Ratings Decibel Cannabis Company Inc.

Equities

Market Closed - Toronto S.E. Other stock markets 10:43:45 28/06/2024 pm IST			5-day change	1st Jan Change
0.05 ^CAD	-16.67%		-23.08%	-61.54%

29/05	Decibel Cannabis Company Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
29/04	Decibel Cannabis Company Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

The company's profit outlook over the next few years is a strong asset.
Its low valuation, with P/E ratio at 2.5 and 1.43 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
The stock, which is currently worth 2024 to 0.56 times its sales, is clearly overvalued in comparison with peers.
The company has a low valuation given the cash flows generated by its activity.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Over the past twelve months, analysts' opinions have been revised negatively.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
DECIBEL CANNABIS COMPANY INC.	-61.54%	1.79Cr		-
DONG-E-E-JIAO CO.,LTD.	+26.93%	559.76Cr		B-
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-33.55%	353.05Cr		C+
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-3.74%	302.97Cr		C
TASLY PHARMACEUTICAL GROUP CO., LTD	-26.09%	258.15Cr		B-
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-10.93%	230.75Cr	-	D+
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+41.50%	185.97Cr		-
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+41.84%	144.94Cr		-
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK	+47.62%	141.07Cr		-
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-28.07%	126.88Cr		C-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality